Abbott

BinaxNOW™ COVID-19 Ag CARD AND NAVICA™ APP

Abbott's BinaxNOW COVID-19 Ag Card is a rapid, highly portable, reliable and affordable tool administered by a healthcare provider for detecting active coronavirus infections on a massive scale, helping slow the spread of the virus. BinaxNOW, combined with the NAVICA app, was designed to help people feel more confident in their daily lives.

PORTABLE AND EASY TO USE

Size of a credit card

Use with a nasal swab

No equipment required



COVID-19 TEST
NAVICA MOBILE APP

FAST

15 minutes for result

RELIABLE

Demonstrated sensitivity of 97.1% and specificity of 98.5% **in clinical study**

CONNECTIVITY

Complementary NAVICA mobile app stores and displays test results to help facilitate safer access to organizations where people gather, such as workplaces and schools

To learn more about antigen testing and the science behind it, visit **www.navica.abbott**.

DISCLAIMER: The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

ON THE GO?
TESTING THAT TRAVELS WITH YOU.

Any United Airlines customer traveling back to the U.S. from an international destination will have access to Abbott's BinaxNOW™ COVID-19 Ag Card Home Test and NAVICA™ app.

HOW IT WORKS

ORDER YOUR TEST

United's Travel-Ready Center gives you the option to purchase Abbott's BinaxNOW Home Tests through eMed, which will be shipped to you before your flight.

PACK YOUR TEST IN YOUR CARRY-ON

Passengers receive the tests in the mail and pack the unopened tests in their carry-on bag.

CONDUCT THE TEST BEFORE YOUR FLIGHT HOME

No more than three days before departing, the traveler logs into eMed where a live certified guide walks you through the testing process.

GET YOUR NAVICA DIGITAL HEALTH CERTIFICATE

If test results are negative, eMed will send a digital health certificate through the NAVICA app. If a test result is positive or inconclusive, United's Travel-Ready Center can help the passenger with additional information.

TRAVEL HOME WITH EASE

Travelers show their NAVICA pass to United Airlines personnel when checking in for their flight home.

The BinaxNOW™ COVID-19 Ag Card Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for prescription home use with self-collected observed direct anterior nasal (nares) swab samples from individuals aged 15 years or older who are suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset or adult collected nasal swab samples from individuals aged four years or older who are suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.

The BinaxNOW COVID-19 Ag Card Home Test is to be performed only with the supervision of a telehealth proctor.

For more information on testing, visit United's Travel-Ready Center.

For more information on Abbott's BinaxNOW COVID-19 Ag Card Home Test, visit Abbott.com

Abbott

INTRODUCING

NAVICA™ MOBILE APP AND BinaxNOW™ COVID-19 AG CARD

TAKING COVID-19 TESTING TO A **NEW LEVEL**

Designed to Restore Confidence in Daily Life

The revolutionary NAVICA™ app helps people navigate daily life in a new normal. NAVICA displays results from the 15-minute Abbott BinaxNOW™ COVID-19 Ag Card, an antigen rapid test, to help individuals make informed decisions.

This first-of-its-kind app, available at no charge, allows people who test negative to get an encrypted temporary digital NAVICA Pass, similar to an airline boarding pass. NAVICA-enabled organizations will be able to verify an individual's negative COVID-19 test result by scanning the individual's digital NAVICA Pass to facilitate entry into facilities, along with hand-washing, social distancing, enhanced cleaning and mask-wearing.

Your Role in the NAVICA Process

As a NAVICA-enabled test site, you will use the NAVICA Administrator app to communicate encrypted BinaxNOW COVID-19 Ag Card test results to participants and allow them to obtain a digital NAVICA Pass with a negative test result. To conduct testing at your site, a CLIA-waived license is required per the FDA Emergency Use Authorization for BinaxNOW COVID-19 Ag Card.

As a **BinaxNOW™ COVID-19 Ag Card testing site,** you play an important role in helping people move about with greater confidence.

THE NAVICA™-BinaxNOW TESTING PROCESS IS SIMPLE:

1. Scan the participant's NAVICA ID on their mobile device and verify photo ID match.
2. Scan the unique QR code on the BinaxNOW COVID-19 Ag Card to create a secure link between the participant and the test card.
3. Perform the BinaxNOW COVID-19 Ag Card test, following the package insert instructions.
4. Rescan the QR code on the test card to confirm the link and chain of custody between the BinaxNOW COVID-19 Ag Card test and the participant.
5. Visually interpret the test result on the card and submit the positive or negative result accordingly via the NAVICA app.

The participant will be notified of their result submission through the NAVICA app. A negative result submission will generate an encrypted digital NAVICA Pass as a QR code on the individual's mobile device. If the participant tests positive, they will receive a NAVICA message to follow CDC Guidelines on quarantine and consult their healthcare provider.

Abbott believes the NAVICA app and BinaxNOW COVID-19 Ag Card test will help us recover a bit more freedom, confidence and normalcy in our everyday lives.

BinaxNOW™ COVID-19 AG CARD

A Breakthrough Antigen Test

SIMPLIFYING THE TEST PROCESS

- Cost-effective, high performing test designed for decentralized testing
- Simple test procedure
  - —Direct nasal swab
  - —Onboard extraction allows the swab to be directly inserted into the test card
  - —Visually read results in 15 minutes (no instrument required)
- Emergency Use Authorization (EUA) supports testing in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation*

PERFORMANCE

Sensitivity (PPA) **97.1%**

Specificity (NPA) **98.5%**

Direct nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.

TEST PROCEDURE**

1. Add the extraction reagent



2. Insert the sample nasal swab



3. Rotate the nasal swab shaft three times



4. Close the test card; wait 15 minutes

5. Results are read visually

KIT CONTENTS

- 40 Test Cards
- 40 Nasal Swabs
- Positive Control Swab
- Reagent Bottle
- Package Insert
- Procedure Card
- 40 Patient COVID-19 Fact Sheets
- Healthcare Provider COVID-19 Fact Sheet

ORDER INFORMATION

PRODUCT NAME	PRODUCT CODE
BinaxNOW™ COVID-19 Ag CARD 40 CT	195-000
BinaxNOW™ COVID-19 Ag CARD CONTROL KIT (10 POSITIVE)	195-080

NAVICA | Download on the App Store | GET IT ON Google Play

NAVICA APP AVAILABLE FOR DOWNLOAD ON THE APP STORE® AND GOOGLE PLAY™
NAVICA.ABBOTT

FOR MORE INFORMATION, CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE OR VISIT BINAXNOW.NAVICA.ABBOTT

* Before testing patients, federal regulations require testing sites to have a CLIA certificate issued by CMS. Sites performing only waived tests must obtain a Certificate of Waiver by applying for this certification for each location performing testing.

**Refer to the product package insert for full instructions.

App Store and the Apple Logo are registered trademarks of Apple Inc.

Google Play and the Google Play logo are trademarks of Google LLC.

The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.
Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. 120006904-04 08/20

Abbott

Reporting Patient Results Using NAVICA

Upon completion of the test and result interpretation, the telehealth proctor will send your test results via the NAVICA app. You will be notified by email and on your mobile device that our results are ready. You will get the results screen of NAVICA to obtain your test results





VS



Abbott

ONLINE NEWSLETTER SAMPLES

Abbott's new NAVICA app: What you need to know

The app pairs with Abbott's new COVID-19 antigen test to help facilitate easier access to organizations and other locations where people gather.



Abbott Newsroom Feedback

DIAGNOSTICS TESTING | Aug. 26, 2020

Editor's Note: As of June 13, 2022, the U.S government has removed the requirement of a negative COVID-19 result to return to the U.S. As more parts of the world reopen and we co-exist with COVID-19, fast and reliable rapid tests will remain a critical tool. You can find more

By using this site, you agree with our use of cookies. I consent to cookies Want to know more?

gather in the U.S. are grappling with decisions about whether to open and how broadly to do so, as cases of COVID-19 continue rising in parts of the country. If only there were an easy way to identify people who have tested negative for the virus.

Good news — now there is.

Abbott's new rapid antigen test — the BinaxNOW™ COVID-19 Ag Card — has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). The test pairs with an optional app called NAVICA™ that works like a secure mobile boarding pass, which can be scanned to facilitate easier entry into organizations and facilities.

Chris Scoggins, Abbott's senior vice president, Rapid Diagnostics, answers the five most pressing questions about this first-of-its-kind app that will be available at no charge.

Check it out:

1. What is the NAVICA App?

This is a new app that Abbott designed to pair with our BinaxNOW rapid antigen test for COVID-19. The app works on iPhone and Android devices and allows people to store, access and display their BinaxNOW test results so we can more confidently return to life.

2. How Does the App Work?

When you get Abbott's BinaxNOW test at a NAVICA-

By using this site, you agree with our use of cookies.

only to you and those whom you choose to share them with.

If you test negative, the app will display a temporary encrypted digital pass with a QR code, similar to an airline boarding pass. The pass will be renewed each time a person takes a new test and receives a negative test result and will include the date of the latest test result. Organizations will be able to view and verify the information on a mobile device to facilitate entry into facilities along with hand-washing, social distancing, enhanced cleaning and mask-wearing. If you test positive, you'll receive a message in the app to quarantine and talk to your doctor.

3. What are the Key Benefits of the NAVICA App for Consumers?

It's all about helping restore a sense of normalcy. Helping people get back to doing the things they love with a little more confidence than they've had during the pandemic.

...for Healthcare Providers?

Many frontline health workers are overwhelmed with people who need to be tested or treated for COVID-19. The NAVICA app allows healthcare providers in all settings to easily display test results to their patients and customers.

...for Organizations like Employers, Schools and Other Places Where People Gather?

By using this site, you agree with our use of cookies.

results of our BinaxNOW test, may help reduce the risk of virus spread and increase confidence at places where people tend to gather in large numbers.

4. Where can People Get the App?

The NAVICA app can be downloaded for no charge in the U.S. from the App Store [Apple devices] and the Google Play Store [Android devices]. After downloading the app, you just enter some basic information. The whole process takes about two minutes.

5. How is Abbott Protecting the Security of Personal Information in the App?

Maintaining customers' privacy is always a priority for Abbott. When it comes to the NAVICA app, the data transmitted are encrypted. And users only share their first and last name, email address, phone number, zip code, and date of birth, which limits the sensitive identifying data being shared in the first place. Additionally, the app isn't used for contact tracing, so personal location information is not being tracked or shared.

Want to know more?

Get a closer look at our NAVICA app and our new BinaxNOW rapid antigen test for COVID-19.

The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by

By using this site, you agree with our use of cookies.

authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Like This Article

MOST READ

HEALTHY HEART

Nov. 20, 2023

SMALLEST MECHANICAL HEART VALVE SAVED HER LIFE

Baby Sadie received the world's smallest mechanical heart valve, and her life instantly changed. Today, she's a spunky 9-year-old.

By using this site, you agree with our use of cookies.

BinaxNOW + NAVICA App Among Chicago's Best Innovations

Chicago Innovation Awards honors BinaxNOW, the first rapid antigen COVID-19 test that doesn't need instrumentation.



STRATEGY AND STRENGTH | Oct. 19, 2020

When Wallace Abbott first opened the doors to his pharmacy in Chicago's Ravenswood neighborhood, Illinois was one of 38 United States.

Dr. Abbott was 15 years ahead of the Wright Brothers'

By using this site, you agree with our use of cookies. I consent to cookies Want to know more?

Abbott Newsroom Feedback

moon, through the fall of the Berlin Wall and to the rise of the Internet, Abbott is still here — and stronger than ever — because it has never stopped evolving.

For one very simple reason: "Necessity."

"As a company that's been in business for more than 130 years, Abbott provides a clear illustration. You might assume that a company that old will be slow, backward looking, set in its ways. But — almost by definition — that can't be true because a company can't last 130 years without reinventing itself constantly for the changing world around it."

Those words — delivered Monday by Abbott Executive Chairman Miles White during a special keynote address to the 2020 Chicago Innovation Awards celebration — make clear the foundation on which our company has operated since 1888.

For that commitment to continual reinvention, the company has been honored myriad times for its technological breakthroughs.

This year proved the power of "necessity" for innovation like no other.

With the world gripped by the coronavirus pandemic and a vaccine not yet a reality, one of the best hopes to getting back to something of normalcy lies in access to fast, reliable, affordable COVID-19 testing at massive scale.

By using this site, you agree with our use of cookies.

the FDA that doesn't require any instrumentation — is exactly what the world needs now: fast, reliable, affordable and available on a massive scale.

"It could be used by healthcare professionals in a variety of locations such as schools and workplaces," said Abbott President and CEO Robert Ford in accepting the award on behalf of the company. "And BinaxNOW pairs with our complementary mobile app NAVICA, which displays users' test results. With this combined solution, a person's COVID status can be quickly verified to provide confidence in accessing common gathering places."

And it's why BinaxNOW and NAVICA were among those honored by the Chicago Innovation Awards.

This year's award marks the 11th in the Chicago Innovation Awards' 19 years that Abbott has been recognized, the most by any company.

Previous Abbott winners include:

2019 for Amplatzer Piccolo Occluder

2018 for FreeStyle Libre

2017 for Similac Pro-Advance and Similac Pro-Sensitive

2015 for MitraClip

2010 for ARCHITECT HIV Ag/Ab Combo Test

2009 for Similac SimplePac container

By using this site, you agree with our use of cookies.

2007 for Abbott m2000 molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test

2005 for PathVysion breast cancer test

2003 for HUMIRA, a biologic treatment for certain immunological diseases.

Note: HUMIRA is no longer an Abbott product. More information is available here.

"We'd like to express our sincere gratitude to the Chicago Innovation Awards for recognizing the Abbott people around the world who've worked 24/7 this year to develop this important test to help beat the virus," Ford told the virtual gala. "We also want to congratulate our fellow honorees who are doing so much to make Chicago a thriving and dynamic global hub for innovation."

Indeed, the Chicago area has long been the home of high-flying companies with big ideas about how to make the world a better place.

"'Pioneering' is one of our stated core values, taught to every Abbott person," White told the audience. "We make it clear to everyone who joins the company — and continually thereafter — that we're here to create the future of healthcare. And we make it equally clear that the same principle applies in everything we do as a company — not just the lab. Because everything can always be better, and it's our job to make it that way.

By using this site, you agree with our use of cookies.

The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Like This Article

MOST READ

HEALTHY HEART

Nov. 20, 2023

By using this site, you agree with our use of cookies.